Biopharma Market Review and Outlook (Pharmaceutical Executive, October 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in the first half, and the outlook for 2023.
Chem Financing to Remain Challenged (ICIS Chemical Business August 18 – August 24, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed Financings and the outlook for 2023.
Chemical M&A Activity Turns Up (ICIS Chemical Business August 11 – August 17, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed M&A and the outlook for 2023.
Young & Partners Biotech Financing Review and Outlook (June 21, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Chemical M&A Review and Outlook (June 5, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Pharma M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Biotech M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Biopharma M&A: Year in Review, Ripples Ahead (Pharmaceutical Executive, March 2023)
Young & Partners shares analysis of the global disruptions and uncertainties that have affected Biopharma M&A and the outlook for 2023.
Debt Financing to be difficult in 2023 (ICIS Chemical Business February 3 – February 9, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed Stock Prices and Financings and the outlook for 2023.
Young & Partners Pharma and Biotech M&A Review and Outlook (January 20, 2023)
Proprietary data and analysis of 2022 and the current outlook.